Podcasts about semaglutide

2x Mr. Olympia Runner-Up, 2x Arnold Classic Champ, USAF Veteren, one of the greatest posers of this era & potentially of all time, and one of the top contenders for the Classic Mr. Olympia title in 1 weekThe Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:0:00 Intro2:19 Breathing Fixes in Prep4:29 Coaching Shift & Gym Updates00:07:13 Pricing Real Talk00:08:19 Success Mindset 16:01 Olympia Plans & Prize Money Talk 18:38 Mr Olympia Beyond Bodybuilding00:21:46 Weider Influence & Sport Growth 27:05 Stage Setup & Judge Analysis 31:46 Jose's Improvements 36:59 Years Left in the Sport 41:42 NY Pro Peak 45:52 Carb Boost Strategy 49:43 Dehydration Fatigue 55:15 Rhomboid Focus 1:02:04 RPG Love 01:07:29 Friend Support 01:15:53 Olympia Packing Insight 1:25:33 Training Priority 1:34:05 Life Purpose Beyond BB 01:38:15 Legacy Building 01:45:03 Hair Transplant & Aesthetic Shift 01:54:21 Transformation 02:05:00 Final Message

PhDc endo & expert on bodybuilding pharmacology & enhanced bodybuilding scienceWatch it: https://www.youtube.com/watch?v=LXErTWYFxBM&lc=Ugyh4j4EKOMWMx7bCDd4AaABAg.ANg5e8KTLa5ANgOVCTnFlCThe Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.com00:00:00 Intro00:04:06 Book Updates & GH Research00:08:55 GH, DHT & Acromegaly00:13:29 GLP-1 & Offseason Nutrition00:18:10 Classic vs Open Bodybuilding00:24:31 Leg Growth & Fiber Types00:28:41 Time Off Gear & Recovery00:34:49 Training Frequency & Volume00:41:18 Prep Cycles & Orals00:46:48 Diet & Fullness Strategies00:49:36 Moving & Compound Reactions00:51:32 GI Health & Peptides00:55:49 Cardio & Skin Thickness01:03:05 Sleep Solutions & Aids01:10:32 Choline & Cognitive Health01:12:20 Surgery Recovery & Female HGH01:18:17 Blood Pressure & Hematocrit01:25:10 Cardio, Fat Loss & Yohimbine01:33:08 Favorite Bodybuilders & GH Dosing01:39:43 GH Injecting best practices01:43:53 Final Message to the world

THE NATURAL GLP-1 SUPPLEMENT STACK

Welcome to The Peptide Podcast. In this episode, we're unpacking the latest on retatrutide and how it measures up against semaglutide and tirzepatide.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  https://pepties.com/partners/ We'll look closely at what the studies tell us so far — from overall weight loss to reductions in visceral fat and how much lean muscle mass is preserved. We'll also talk about where the evidence is solid, where it's still developing, and why cross-trial comparisons should be made with caution. What is retatrutide? So let's start with the basics—what is retatrutide? Retatrutide is a new type of weight-loss medication called a triple agonist. That sounds fancy, but what it really means is that it targets three hormone receptors in the gut and pancreas: GLP-1, GIP, and glucagon. Each of these plays a slightly different role in metabolism and appetite regulation. To break it down: GLP-1, which you might already know from drugs like semaglutide, mainly slows digestion, helps you feel full, and improves insulin sensitivity. GIP, which tirzepatide targets along with GLP-1, also helps regulate blood sugar and may improve how the body stores and burns fat. Retatrutide adds glucagon receptor activation on top of that, which seems to further boost fat burning. So how does this compare to semaglutide and tirzepatide? Semaglutide is a GLP-1-only drug, so it mainly works by reducing appetite and slowing gastric emptying. Tirzepatide is a dual agonist, hitting GLP-1 and GIP, which gives it a slightly stronger effect on blood sugar control and fat metabolism compared to semaglutide. Retatrutide goes one step further by adding glucagon activity, potentially giving more total fat loss. In other words, you can think of it like a spectrum: semaglutide hits one target, tirzepatide hits two, and retatrutide hits three—each additional receptor seems to enhance metabolic effects and fat loss in clinical trials. That's why people are excited about retatrutide, though it's still early, and we're waiting on larger studies to see exactly how it compares head-to-head with the others. And that's going to be key, since right now we don't have direct comparisons to other advanced therapies like semaglutide or tirzepatide in the published Phase 2 data. How does retatrutide compare to semaglutide and tirzepatide? Total body weight loss: Now let's put these three medications side by side and look at what the trials actually tell us about total body weight loss. Starting with retatrutide: in its Phase 2 obesity program, the numbers were unusually large, especially given the relatively short trial window. In the 48-week study, people on the higher doses—8 or 12 milligrams weekly—lost about 22 to 24% of their body weight on average. That's the result that really made headlines. It's worth noting that some trials report slightly different averages depending on the group studied—people with obesity but no diabetes versus people with type 2 diabetes—but across the board, that 48-week signal is consistently very strong. For comparison, let's step back to semaglutide at the 2.4 mg dose, which was tested in the pivotal STEP-1 trial. Over 68 weeks, participants lost about 15% of their body weight on average. That was a landmark finding when it was published in the New England Journal of Medicine—it essentially set the modern benchmark for what a GLP-1 monotherapy could do. Then we have tirzepatide, the dual GIP and GLP-1 agonist. The SURMOUNT-1 trial, which ran for 72 weeks, showed dose-dependent results: about 15% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to only around 3% with placebo. Other obesity studies with tirzepatide have backed this up, especially at the higher doses. And in head-to-head comparisons with semaglutide, tirzepatide has consistently come out on top. So if we zoom out: retatrutide's Phase 2 data suggest the greatest average reductions—over 22%—in less than a year. Tirzepatide follows closely behind with around 21% over 72 weeks. And semaglutide shows very meaningful, but smaller, weight loss of around 15% over a similar time frame. The big caveat here is that these aren't perfect apples-to-apples comparisons. The trials differed in their length, the types of patients enrolled—some had type 2 diabetes, some did not—their baseline weights, and even the way results were reported. Plus, retatrutide is still in Phase 2 for obesity, whereas semaglutide and tirzepatide already have large Phase 3 programs and real-world data backing them up. Visceral fat reduction: Next, let's talk about visceral fat reduction—that's the deep fat that surrounds organs like the liver, pancreas, and intestines. It's particularly important because high levels of visceral fat are strongly linked to cardiometabolic disease. Starting with retatrutide, one of the Phase 2 substudies used DEXA scans to measure body composition in detail. At the higher doses—8 and 12 milligrams per week—participants saw visceral fat drop by about 29 to 31% over 48 weeks. That's a very large relative reduction in under a year and one of the reasons people are excited about retatrutide's potential not just for weight loss, but also for improving long-term metabolic health. How does that compare to the other drugs? With semaglutide, we also have DEXA and imaging substudies from the STEP program and follow-up mechanistic work. These consistently show meaningful visceral fat reductions, along with improvements in the ratio of lean to fat mass. The difference is that semaglutide studies typically report VAT changes as “significant and clinically relevant,” but they don't always publish one clear headline number that's directly comparable to retatrutide's ~30%. In other words, semaglutide definitely lowers visceral fat, but depending on the study and population, the exact percentage looks different. For tirzepatide, we also have imaging-based data from the SURMOUNT trials and related body-composition studies. These show that the majority of weight lost is fat mass—including a significant portion of visceral fat. Some analyses report reductions on par with what's seen with GLP-1 therapies, while others suggest tirzepatide may push a bit further. But again, the actual percentages vary depending on whether the study used DEXA, CT, or MRI, and on who was enrolled. The big caveat here is that we don't yet have a head-to-head imaging study comparing all three drugs in the same population with the same methods. Retatrutide's ~30% visceral fat drop is certainly eye-catching, but without that kind of standardized comparison, it's hard to say definitively whether it's truly better than semaglutide or tirzepatide. Lean muscle mass preservation: Now let's shift to lean mass preservation, which is just as important as total weight or fat loss. Across all of the modern obesity drug trials, one thing has been consistent: most of the weight people lose is fat, but some lean tissue is lost too. That's expected whenever you're in a sustained calorie deficit. The question is how much muscle is preserved, and how the proportions break down. With retatrutide, the DEXA substudy showed something reassuring. Even though people lost a lot of total weight and fat, the proportion of lean mass lost compared to total weight loss was similar to what we see with other therapies. In other words, the drug seems to drive large fat reductions without causing disproportionate muscle loss. Interestingly, the absolute amount of lean tissue lost in kilograms was pretty stable across different doses, even though fat loss varied quite a bit. That suggests the extra weight loss with higher doses is really coming from fat, not muscle. Looking at semaglutide, the STEP trials with DEXA scans reported the same general pattern. People lost more fat than lean mass, and when you adjust for the total weight loss, body composition actually improved. In fact, some analyses showed a slight increase in the percentage of body weight that was lean tissue, even though the absolute lean mass in kilograms went down. So again, it's not that muscle isn't affected—it is—but fat loss makes up the majority of the change. For tirzepatide, the SURMOUNT body-composition studies found that about 75% of the weight lost is fat and about 25% is lean mass. That split is very similar to what was seen in the placebo groups, which means the drug isn't shifting the balance unfavorably. It preferentially reduces fat, while lean mass preservation is in the same ballpark as semaglutide and retatrutide. Now, here's the important nuance: lean mass on a DEXA scan isn't just skeletal muscle. It includes water, organ tissue, and other components. So if someone loses 3 or 4 kilograms of “lean mass,” we don't know how much of that is functional muscle versus water or smaller organ size. That's why these numbers can be misleading if you take them at face value. And this is where lifestyle comes in. Resistance training and adequate protein intake are critical alongside medication. Lifting weights or doing bodyweight resistance work helps preserve functional muscle, while getting enough protein—typically somewhere in the range of 0.8 to 1 gram per pound per day depending on age and activity—supports muscle repair and maintenance. Every trial we've seen shows that the best outcomes, in terms of maintaining strength and function, come from pairing these drugs with exercise and nutrition strategies. That way, the unavoidable lean mass changes have far less impact on long-term metabolic health and performance. Limitations, biases, and what's missing (the critical context). No large, peer-reviewed head-to-head trials (yet) comparing retatrutide with semaglutide or tirzepatide for the same endpoints using identical imaging protocols. Most comparisons are cross-trial and therefore imperfect. Retatrutide Phase-2 was often compared to placebo or dulaglutide (in the T2D DEXA substudy) rather than to semaglutide or tirzepatide. A head-to-head (planned/registered) study vs tirzepatide is listed on ClinicalTrials.gov but results are not published yet. Different populations & durations. Some retatrutide data come from cohorts that include people with T2D or NAFLD; semaglutide STEP trials were often in people with obesity (without diabetes) and run longer (68 weeks), while tirzepatide SURMOUNT trials ran to 72 weeks. These differences change the absolute and percent outcomes. Funding and reporting bias. Many of the early retatrutide analyses are industry-funded (Eli Lilly), which is standard for drug development, but it requires us to carefully read methods, endpoints, and completeness of reporting. Independent replication and Phase-3 confirmation matter. Imaging method variation. VAT reported by DXA vs MRI vs CT are not directly interchangeable. Some trials report VAT area, others percent change; that complicates cross-trial percent comparisons.  Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend. Until next time, be well, and as always, have a happy, healthy week.

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospital Diabetes and Metabolic Care Center, discuss the recently published results of the ATTAIN-1 and STEP UP clinical trials, both of which were presented at the European Association for the Study of Diabetes (EASD) 2025 Conference. 00:00:00 Introduction 00:00:32 ATTAIN-1 00:04:07 GLP-1s as a Daily Pill 00:08:20 Possible Lower GLP-1 Prices 00:09:03 STEP UP 00:11:41 Cardiovascular Protection with GLP-1s 00:12:48 GI Side Effects of Semaglutide 7.2 00:16:16 3 Times the Dose, 3 Times the Cardiovascular Protection? 00:17:20 Outro

September is Cholesterol Education Month. In this episode of Intelligent Medicine, Jim LaValle, a clinical pharmacist and certified clinical nutritionist, details cholesterol's importance and its implications for cardiovascular health. He delves into the nuances of cholesterol types, the historical shifts in perceptions of cholesterol, and how dietary and lifestyle factors influence cholesterol levels and cardiovascular risk. Jim provides expert insights into the roles of LDL and HDL cholesterol, the significance of cholesterol particle size, the impact of carbohydrates on cholesterol, and the benefits of aged garlic extract and other supplements. The conversation emphasizes the importance of comprehensive lipid testing, understanding individual risk factors, and integrating both lifestyle modifications and, when necessary, medications into cardiovascular preventive strategies. The episode concludes with a discussion on the role of health policies and the future of integrative health approaches.

Dr. Hoffman continues his conversation with Jim LaValle, a clinical pharmacist and certified clinical nutritionist, detailing cholesterol's importance and its implications for cardiovascular health. 

In this episode of the Ageless Future Podcast, Regan Archibald sits down with Dr. Tyna Moore, a bold voice in regenerative medicine, to explore the promise and pitfalls of GLP-1 peptides. Known for her controversial stance on individualized, low-dose prescribing, Dr. Moore challenges conventional medicine's one-size-fits-all approach, advocating instead for “slow and low” dosing tailored to each patient's biology. The conversation covers why GLP-1s are more than just weight-loss tools, their potential in cardiovascular, brain, and metabolic health, and the importance of foundational practices like strength training, gut health, and movement. Dr. Moore also shares her personal journey through chronic illness, the limitations of traditional medicine, and her vision for a future where patients are empowered with optimized, personalized care.Website: www.drtyna.com Info: www.drtyna.com/ozempicuncovered LIKE/FOLLOW/SUBSCRIBE DR. TYNAInstagram: https://www.instagram.com/drtynaYouTube: https://youtube.com/@drtynaPodcast: https://podcasts.apple.com/us/podcast/the-dr-tyna-show/id1577258582

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-451 Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year. Episode resource links: Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064.  Moiz A, Filion KB, Toutounchi H, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025;178(2):199-217.  Wen J, Syed B, Nadora D, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinol Diabetes Metab. 2025;8(3):e70045.  Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-451 Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year. Episode resource links: Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064.  Moiz A, Filion KB, Toutounchi H, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025;178(2):199-217.  Wen J, Syed B, Nadora D, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinol Diabetes Metab. 2025;8(3):e70045.  Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Join Drs. Neil Skolnik and Sara Wettergreen as they answer one of the most common questions people living with diabetes have: “What diabetes medication is best for me?”   In this episode, they'll explore how choosing the right medication depends on your individual health, lifestyle, and goals. Discover practical tips to better help you work with your care team to make informed decisions and find the best treatment plan for you.   Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   Diabetes Medications: Biguanides Brand: Glucophage, Fortamet, Glumetza Generic: Metformin, Metformin XR Sulfonylureas (Second Generation) Brand: Glucotrol, Amaryl, Diaβeta, Glynase Generic: Glipizide, Glipizide XL, Glimepiride, Glyburide Thiazolidinediones (TZDs) Brand: Actos, Avandia Generic: Pioglitazone, Rosiglitazone (no longer available) DPP-4 Inhibitors Brand: Januvia, Onglyza, Tradjenta, Nesina Generic: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin SGLT2 Inhibitors Brand: Invokana, Farxiga, Jardiance, Steglatro, Brenzavvy Generic: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Bexagliflozin GLP-1 Receptor Agonists Brand: Victoza, Trulicity, Ozempic, Rybelsus, Mounjaro (dual GIP/GLP-1) Generic: Liraglutide, Dulaglutide, Semaglutide, Tirzepatide Insulins (selected examples) Brand: Humalog, NovoLog, Apidra, Lantus, Basaglar, Levemir, Tresiba, Humulin N, Novolin N, Humulin R, Novolin R Generic: Insulin lispro, Insulin aspart, Insulin glulisine, Insulin glargine, Insulin detemir, Insulin degludec, NPH insulin, Regular insulin

In parts 1 and 2 we looked at studies that sought to determine the effects of semaglutide on kidney function. Today, in the final part of the series, we are going to discuss another such study called Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes by Perkovic et al., 2024. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

En este episodio hablo con el Dr. Javier Muñoz sobre la hormona GLP-1, más conocida como Ozempic, Semaglutide o Mounjaro. Descubrí qué hay detrás del boom mundial: sus beneficios reales, cómo actúa en el cuerpo y lo que nadie te cuenta.Disclaimer: Este episodio es educativo e informativo. No sustituye la consulta médica.Dale play y compartilo con alguien que también quiera entender de qué se trata todo este boom del GLP-1.Recordá: cuidar tu cuerpo también es honrar el regalo de la vida.

Send us a textWhat if everything you thought you knew about weight loss was wrong? In this powerful conversation, Joey Pinz sits down with Dr. David Plourdé—scientist, author of Solving the Weight Loss Puzzle, and founder of The Plourde Method—to uncover the real science behind lasting fat loss.Dr. Plourdé shares insights from 34 years in the lab, where he studied fat cells, food addiction, and the hidden forces sabotaging our health. From uncovering insidious carbs in everyday foods to exposing the dark side of weight-loss drugs like Ozempic, his revelations will make you rethink nutrition, exercise, and the role of psychology in transformation.✨ Top 3 Highlights:

Sick of trying fad diets that just don't seem to work for you? Find out how to simplify your approach and succeed by learning and applying the principles of weight management.  How to make calories work for you Which proteins are better than others and when to eat protein Preserving lean muscle while losing body fat "Dirty" vs "Clean" diets Including desert and candy during a weight loss journey   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

This is part 2 of my series on the research around GLP-1 drugs for supporting kidney function. In part 1 we looked at Long-term kidney outcomes of semaglutide in ob*sity and cardiovascular disease in the SELECT trial, today we'll look at “Semaglutide in patients with overw*ight or ob*sity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial” Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

AI accelerates drug discovery while steroids turn teens into aggressive strangers. Dr. Michael Israetel explores our pharmaceutical crossroads here!Full show notes and resources can be found here: jordanharbinger.com/1209What We Discuss with Michael Israetel:GLP-1 drugs like Tirzepatide offer massive health benefits beyond weight loss — reducing inflammation, improving brain health, and decreasing addiction behaviors, even for people already in good shape.Steroids don't just amplify personality — they specifically amplify masculine traits like aggression and reduce empathy. Starting young can permanently rewire your brain's emotional and social processing.AI is about to revolutionize medicine by testing millions of drug candidates virtually, creating treatments 10x more effective with 10x fewer side effects. We're entering the pharmaceutical iPhone moment.The "only take drugs when sick" mindset worked in the 20th century, but is becoming dangerously outdated — like refusing elevators because you prefer human operators.When your diet plateaus, take a week-long break eating at maintenance. Your stress hormones will drop, body water will flush out, and you'll often look leaner than before.And much more...And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:Saily: 15% off: saily.com/jordanharbinger, code JORDANHARBINGERDripDrop: 20% off: DripDrop.com, code JORDANLinkedIn Jobs: Post your job for free: linkedin.com/jordanQuince: Free shipping & 365-day returns: quince.com/jordanBetterHelp: 10% off first month: betterhelp.com/jordanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Shana Hussin, RDN, shares the replay of her recent webinar on GLP-1 — the hormone behind today's most popular weight loss drugs like Ozempic, Wegovy, and Mounjaro. You'll learn: ✔️ What GLP-1 is and how it works in the body ✔️ Natural ways to increase GLP-1 for fewer cravings, better blood sugar, and fat loss ✔️ Lifestyle habits that decrease GLP-1 and fuel insulin resistance ✔️ The truth about GLP-1 medications: cost, side effects, and sustainability ✔️ How to safely transition off GLP-1 drugs by improving natural GLP-1 and gut health ✔️ The research behind Unimate Yerba Mate and Balance Fiber Matrix — and how they support GLP-1 signaling in the Feel Great System ✨ If you've ever wondered whether you really need expensive GLP-1 medications, or if there's a more sustainable, root-cause solution, this episode is for you. Resources & Links:

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Open Bodybuilding Olympian, 3x IFBB Pro Champion, pro podcaster in the IFBBAMA and can be often seen on Bodybuilding & Bollocks on the Real Bodybuilding Podcast.Watch it: https://youtu.be/gPfRK3HoAAYThe Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00 Intro to James Hollingshead04:40 Early Bodybuilding Journey and Influences09:18 Deep Dive into Nutrition and Longevity19:16 Steroid Use and Its Impact on Career26:14 Mindset and Overcoming Hardships38:00 Health Monitoring and Genetics46:20 Optimizing Training Splits57:46 Balancing Bodybuilding and Mental Health01:07:25 Dealing with Loss and Finding Purpose01:18:56 Favorite Prep Memories01:26:04 Best Peaking Show Memories01:33:27 Truth About Dosages01:45:36 Rep Ranges for Hypertrophy01:51:35 Offseason Strategy: Mass vs Conditioning01:55:24 Fertility While on Cycle01:57:14 Favorite Compounds02:00:02 Appreciating the Whole Physique02:04:23 Views on Lifting Styles02:07:51 Balancing Fatherhood and Bodybuilding02:14:45 Therapy and Travel Insights02:17:56 Final Message to the World

Olivia emailed us sharing her personal journey with Semaglutide, a GLP one receptor agonist, and how it helped her manage binge eating disorder. Olivia's experience was so compelling and we believe it sheds light on the silence around GLP one drugs and their potential benefits beyond weight loss. Join Georgie as she discusses the implications, potential benefits, and risks of using these medications for binge eating disorder. She also delves into the future of research and the pharmaceutical industry in this space. This episode is a must-listen for anyone curious about the real-life impacts of GLP one drugs on binge eating disorder.For more information, check out these references below:https://www.sciencedirect.com/science/article/pii/S2667368123000268https://www.sciencedirect.com/science/article/abs/pii/S0924977X24000646https://doi.org/10.1016/j.dsx.2020.03.00900:00 Introduction to Olivia's Story01:33 Olivia's Background and Binge Eating Journey05:03 Starting Semaglutide: Initial Experiences09:03 Impact on Mental Health and Relationships18:38 Public Perception and Stigma25:16 Opening Up About Personal Struggles27:42 The Impact of Medication on Binge Eating30:55 Alcohol and Medication Effects33:07 Cognitive Behavioral Therapy and Mental Space38:21 Redefining Life Without Food Noise40:44 Final Thoughts and Recommendations46:26 Research and Future Directions for GLP-1 DrugsConnect with Georgie and the Confident Eaters Coaches: WebsiteFacebookInstagramHave you ever thought, "I know what to do, I just need to consistently do it"? Who hasn't? Sometimes we need accountability. Sometimes we need specific strategies, new tools, or a bit of help. If you are want help to become a confident, sensible eater with 1:1 personalized attention, sign up at ConfidentEaters.com.

Markus Hunter IFBB Pro:  ⁨@Markusfit⁩  The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:0:00 - Intro5:43 - Social Media Perceptions and TikTok Labels10:00 - Content Creation Struggles and Polarization17:15 - Reasons for Mindset Change20:00 - Constructive Criticism and Impact Stories26:43 - Insane Tren Doses and Variations30:00 - Gear, Genetics, and Growth36:38 - Learning Your Body and Coaching45:56 - Sleep Aids and Health Risks50:00 - Crazy Cycle Stories58:19 - Back Training Revelations59:47 - Men's Physique vs. Open Bodybuilding1:10:00 - Chasing the Pro Card Reality1:20:00 - Pro Card Struggles and Triumphs1:28:20 - Importance of Sex in Relationships01:29:56 - Best Prep Look Without Diuretics1:40:22 - Cycle variations01:49:12 - Biohacking for Optimal Performance01:59:40 - Evolving Training Strategies2:10:00 - Next Pod Plans02:12:38 -Best way to use superdrol02:18:57 - Growth Hormone02:30:46 - Gear Guidance for Newbies02:36:05 - Gut Health2:50:00 - Long Prep Secrets02:57:12 - the final message02:59:26 - Being Self/ Family Centered as Men

[00:00] Intro banter and chaotic energy kicks off the show[02:30] Storytime: Jack breaks a door, hilarity ensues[12:00] Commentary on Ozempic, semaglutide, and weight-loss trends[22:45] Is Nelly Furtado Puerto Rican? Plus pop culture weight changes[30:00] The invention of the "Ozempic Olympics" (listener suggestions welcome)[35:15] Gen X slang deep-dive (what phrases will never die?)[43:00] The Rock and celebs adapting to aging—humorously dissected[49:30] The "America Quiz" — challenging each other's patriot knowledge[01:00:00] Wrap-up, random laughs, and Fred's memorable shout-out #blcpodcast #podcastingforthepeople #funny #podcast #greenvillesc #scpodcast #yeahthatgreenville Listen at: https://americasfavoritepodcast.com Tweet the Show: https://twitter.com/blcworld Follow us on Facebook: https://www.facebook.com/blcpodcast/ Check us out on Instagram: https://www.instagram.com/blcpodcast/ Buy Fred and Allan Beer: https://www.patreon.com/blcworld

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review:   1.     Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity  - NEJM   2.     Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3)– Lancet Diabetes Endocrinology    3.     Nutritional priorities to support GLP-1 therapy for Obesity – A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society - American Journal of Clinical Nutrition 4.     Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events – Diab Care 5.     Tirzepatide as Compared with Semaglutide for the Treatment of Obesity – NEJM For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Episode Summary: Summer may have been fun, but if your energy, weight, or motivation feel off, you're not alone. This solo episode is your permission slip to stop the extremes and start fresh—with a metabolism reset grounded in balance, not burnout. Shana walks you through why so many women feel worse after summer, and what to do now to feel amazing again—without restrictive dieting or relying on medications like Ozempic, metformin, or statins. If you're feeling puffy, tired, or stuck, this episode will show you how to gently reset your metabolism, support your hormones, and finally feel great again. 

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation centers on the roles that new technologies and an expanded APP population will play in MASLD and MASH management in the US, and concludes by exploring how care might look different 12 months from now, and then in subsequent years. As panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients, many comments touch on themes discussed earlier in this episode. A couple are unique. Zobair and Scott discuss the increased role that artificial intelligence and big data analytics will play in identifying high-risk patients and improving clinical pathways. Additionally, Zobair notes that we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scott anticipates a "paradigm shift" in which endocrinologists view MASH similarly to how they view retinopathy, neuropathy and retinopathy. Naim suggests that one year will not look tremendously different from today, but that five years from now will be an entirely different picture, which he describes in some detail. 

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00:00 Intro00:02:08 Coaching Men vs Women & Hormone Challenges00:06:55 Discovering Bodybuilding & Early Training Mistakes00:11:26 First Competition & Prep Lessons00:15:39 Diuretics vs Natural Peaking00:21:17 Athlete Examples & Conditioning Standards00:25:37 Precision in Bodybuilding & Coaching Start00:31:50 Success with Physique Athlete & Olympia Journey00:36:00 Meeting & Working with Terrence Ruffin00:44:13 Fullness, Dryness & Peaking Challenges00:49:32 Coach–Athlete Learning Curve & Comparisons00:55:49 Classic Physique: Shape vs Conditioning01:02:42 Defining a Good Coach & Athlete Safety01:08:48 Health Supplements & Blood Work Frequency01:15:10 Downsizing for Classic Physique & Compound Choices01:22:12 Individual Reactions & Instagram Misinformation01:26:56 Food Intolerances & Insulin Sensitivity Tips01:33:55 Blood Pressure & Root Problem Fixes01:34:54 Off-Season Training Focus & Nutrition01:39:48 Intensifiers01:44:36 Coaching Anxiety & Life Perspective Shifts01:51:29 Olympia Wins & Chasing Coaching Legends01:55:25 Tips for Young Self & Helping Athletes02:05:05 Tren in Men's Physique & Side Effect Management02:17:53 Hyacine's Proudest Moment02:20:59 Superior Genetics?02:22:34 Clen Use & Side Effects02:33:52 Dubai Bodybuilding Scene & Gyms02:37:34 Dubai Lifestyle & Safety02:42:12 Advice for New Coaches & Mentorship02:46:50 Final Message & Podcast Wrap-Up

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss  FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices.This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education. Another important benefit may come in terms of coverage. Scott points out that most patients living with obesity but not diabetes are unlikely to have their semaglutide prescriptions covered by commercial insurers. Those living with non-cirrhotic MASH are likely to have semaglutide covered. A separate but related point: Naim reports that ~30% of the MASH patients he sees are taking an incretin agonist at the time of initial visit.

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss the FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on how the US healthcare system must adapt to handle the growing number of MASH and MASLD patients who might seek treatment, given likely increases in publicity and education.The conversation starts with a focus on the implications of semaglutide approval for hepatologists. Naim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process.Zobair shifts to a larger point:  even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. The number of APPs necessary to handle this load and trained to do so does not currently exist in the US. Increased APP training must, and will, become an area for increased investment and focus.After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target, screen, diagnose and treat patients...given sufficient providers (mostly APPs) to treat them. 

Send us a text00:00:00 - Surf's Up, Season 6, Episode 12This week's episode is a special three-part roundtable on the implications of the FDA's recent approval of semaglutide. Naim Alkhouri, Manal Abdelmalek, Scott Isaacs and Zobair Younossi join Roger Green in a discussion that focuses less on specifics of pharmacotherapy and more on how having two drugs available will change MASH management in the US.00:08:45 - Part I: How Will The Semaglutide Approval Affect Patient Treatment and Pharmacotherapy?The group starts by describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education.00:25:30 - Part II: How the Structure of Medical Practice Is Likely To ChangeNaim states that many hepatologists are currently uncomfortable managing patients on GLP-1 agonists. This will need to change. Manal points out that providers must check for cirrhosis when testing for MASH and understand how to respond accordingly. An increase in the number of providers having access to in-office scanning devices will facilitate this process. Zobair states that even if all related specialists integrate MASH into their practices, the actual patient care demand will require alternative pathways in which the responsibility for patient care will rest with specialist APPs. After Naim Alkhouri describes some of the differences between resmetirom and semaglutide in terms of practical treatment decisions, the discussion focuses on why MASLD and MASH will create unique challenges for hepatology practices. Manal views the issue as a matter of time; practices cannot absorb large numbers of new, non-urgent patients. Naim suggests that the real issue is the business question: specialists today do not profit simply from treating patients. Zobair agrees with Naim and notes that the challenge is not unique to hepatology. He expresses the hope that AI and efficient database management will make it easier to target patients, screen, diagnose and treat them. 00:44:17 - Part III: What Happens Next?In this final section, panelists identify some of the changes they foresee if we are to manage the tsunami of undiagnosed MASLD patients. Many of the comments touch on themes discussed earlier in this episode, but a couple are unique. Zobair states we must remember that the vast majority of MASLD patients will never develop MASH. Manal foresees a more sophisticated approach to selecting pharmacotherapies as prescribers have a broader set of options, each with its own benefits and drawbacks. Scotts anticipates a "paradigm shift" in which providers come to view MASH similarly to how they view diabetic comorbidities. 

In this episode of the RWS Clinician's Corner, Margaret Floyd Barry sits down with Dr. Tyna Moore—renowned naturopathic physician, chiropractor, and international speaker with almost 30 years of experience in holistic and regenerative medicine. Dr. Tyna is known for her bold approach to metabolic health, especially her unique use of GLP-1 agonists like semaglutide, not just for weight loss but as powerful tools for longevity, healing, and resilience. Dr. Tyna pulls back the curtain on the true clinical potential of these peptides, busting myths and exploring the nuance lost in today's clickbait headlines.   In this interview, we discuss:   The science behind GLP-1s and GLP-1 Agonists (including mechanism of action and effects) Microdosing/personalized dosing of GLP-1s, including clinical uses beyond weight loss The concept of “cycling” versus lifelong usage (compared to hormone therapy) Potential side effects and dosing management (including contraindications and safety) Compounded GLP-1s: access, regulations, and practicalities Industry resistance, misinformation, and social dynamics Using GLP-1s during gut healing protocols and the limits of natural alternatives The Clinician's Corner is brought to you by Restorative Wellness Solutions.  Follow us: https://www.instagram.com/restorativewellnesssolutions/    Connect with Dr. Tyna Moore: Website: http://www.drtyna.comInstagram: https://www.instagram.com/drtyna/ YouTube: https://www.youtube.com/@drtyna   Click here for Dr. Tyna's Free 4-part video Series, GLP-1 Uncovered. This video series concludes with an offer for her course, GLP-1s Done Right University. Enter coupon code MARGARET to receive a special discount: https://www.drtyna.com/ozempicuncovered   Or, to go directly to the course, GLP-1s Done Right University, click here and enter the same coupon code (MARGARET) to get started.  Timestamps: 00:00 Regenerative Medicine and Hormone Therapy  05:57 Functional Medicine Truth vs. Propaganda  14:17 Regenerative Therapy Requires Low Inflammation  16:08 Widespread Cardiometabolic Health Crisis  22:16 "Managing Health Challenges with Medication"  30:29 "Low-Dose Approach for Diabetes Management"  36:16 "Empowering Patients Through Education"  38:58 Custom Medication Dosing Benefits  44:43 503B Compounding Pharmacies Shutdown  52:51 Understanding Peptides in Modern Healthcare  57:15 Biliary Concerns in GLP-1 Use  59:14 Liver Health and Supplement Advice  01:06:57 Optimizing Gut Microbiome Strategies  01:10:17 "GLP-1 for Health Improvement" 01:15:29 "Rediscovering Physical Fitness" Speaker bio:    With nearly thirty years immersed in the medical field, Dr. Tyna Moore is an expert in holistic regenerative medicine and resilient metabolic health. She is licensed as a Naturopathic Physician and a Chiropractor, drawing on knowledge from both traditional and alternative fields of science and medicine to provide a comprehensive perspective to individuals striving to enhance their health and wellbeing. Dr. Tyna holds degrees from the National College of Natural Medicine, an esteemed naturopathic medical school, and the University of Western States Chiropractic College. Her work is not just about treating symptoms, it's about understanding and healing root causes to build a robust foundation for long term wellbeing. She is well known for her fierce and open-minded exploration of the peptide, Semaglutide/Ozempic, as a longevity tool for healing. Dr. Tyna champions medical autonomy and individual accountability, and she is on a mission to help as many people as possible experience the freedom and joy that health brings.   As the host of The Dr. Tyna Show Podcast, a top ranking podcast in the health and wellness space, and an international speaker, she is dedicated to empowering others to take control of their wellbeing, heal their metabolic health, and build strength and resilience. Her cornerstone recommendations for every patient and listener: weight lifting and sunshine. Additionally, she extends her expertise to support fellow doctors in cultivating their online practices, helping them transition away from the insurance-centric model to reclaim time, financial stability, and freedom.   Dr. Tyna lives in Oregon with her husband and daughter, and is a proud dog mama. Keywords: GLP-1 agonists, semaglutide, tirzepatide, peptides, regenerative medicine, metabolic health, weight loss strategies, microdosing, hormone replacement therapy, insulin resistance, appetite suppression, personalized dosing, compounding pharmacies, side effects, gut health, SIBO (small intestinal bacterial overgrowth), slow motility, inflammation, functional medicine, neuroregeneration, autoimmune conditions, BPC-157, muscle mass, pharmaceutical dosing, diabetes management, cardiovascular health, leaky gut, obesity, perimenopause, patient empowerment, cycling peptides   Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

Those injection-free sublingual GLP-1 drops for individualized microdosing—do they actually work? Options for treating stubborn neuropathy; Her new doctor said, “Vitamins are hogwash”—so she fired him; There is hope for tinnitus—via diet and lifestyle; I'm taking German classes, and a new study suggests it'll help me ward off cognitive decline. 

The most honest & vulnerable this pod has potentially gotten. Death, pain, drugs, cheating in relationships, divorce, mental health adversity, injury leading to inability, & disease, all experienced by one person, alone. That's what many of us men go through and I'm glad Steve opened up about it today.The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]http://www.transcendcompany.com/nylenaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:0:00 Intro & Starting Convo5:19 First Meeting & Bodybuilding Beginnings10:44 Lessons from Adversity15:01 Coaching Nightmare & Recovery17:41 Naivety in Coaching → Self-Education22:49 Relationship Red Flags & Cheating Signs26:10 Porn Addiction & Marriage Impact29:41 Final Confrontation & Fresh Start32:28 Coaching Philosophy & Client Focus36:18 Toxic Relationship Cycles40:54 Gaming Escape & Life Balance42:44 Bouncing Back Strong44:21 Childhood Loss & Emotional Suppression48:24 Healing Through Community51:21 Positive Mindset Shifts54:32 Losing Loved Ones & Grief1:02:10 California Escape & Life Reorientation1:06:34 Pat's Lasting Impact1:11:37 Chosen Bonds & True Friendship1:15:19 Creating Impactful Content1:19:54 Keeping It Real on Social Media1:23:15 PED Experiments & First Prep Dosages1:27:00 Mental Strength & Stoicism1:30:05 PED Effects & Genetic Factors1:44:07 Dexa Scan & Injury Struggles1:48:19 Prep Lessons & Stress Relief1:55:10 Microdosing & Health Phases1:58:13 Travel Nightmares & Food Poisoning2:03:20 Blood Work & Health Optimization2:05:14 Rural Grind & Work Ethic2:08:37 Training Revolution & Physique Evolution2:19:59 Weight Struggles & Bulking Mindset2:23:04 Client Coach Relationships2:29:14 Moderate Dosing & Low Dose Gains2:34:14 Conscious Choices & Coaching Insights2:36:54 Prep Relationship Struggles2:41:06 Relationship Support & Competitive Balance2:43:44 Nutrition Hacks & Insulin Gains2:47:20 Gut Health & Recovery2:53:42 Stretching & Injury Prevention2:56:22 Pro Goals & Offseason Strategy2:58:54 Risk Management & Blood Work3:00:48 Final Message & Positive Impact

Quick summaries of articles 51-60. Enjoy! 51. Fun Activities and Recovery Acuff, S. F., et al. A brief measure of non-drug reinforcement: Association with treatment outcomes during initial substance use recovery. Drug and Alcohol Dependence, 256, 111092. 52. Buprenorphine-precipitated Fentanyl Withdrawal Thakrar AP, et al. Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl. JAMA Netw Open. 2024 Sep 3;7(9):e2435895. 53. Methadone Vs. Buprenorphine Nosyk B, Et al. Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA. 2024 Oct 17. 54. High Daily Doses of Buprenorphine Axeen S, et al. Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization. JAMA Netw Open. 2024 Sep 3;7(9):e2435478. 55. How Buprenorphine Works in Pregnancy Caritis, Steve N. MD; et al. A Pharmacologic Evaluation of Buprenorphine in Pregnancy and the Postpartum Period. Journal of Addiction Medicine ():10.1097/ADM.0000000000001380, September 2, 2024. 56. How Many Quite Attempts Does It Take? Fontes RM, et al. Beyond the first try: How many quit attempts are necessary to achieve substance use cessation? Drug Alcohol Depend. 2024 Dec 8;267:112525. 57. What is Recovery? Zemore SE, et al. Understanding the Shared Meaning of Recovery From Substance Use Disorders: New Findings From the What is Recovery? Study. Subst Abuse. 2023 Sep 15;17:11782218231199372. 58. Semaglutide for Alcohol Use Disorder (The RCT) Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Feb 12:e244789. 59. Low-Dose Buprenorphine Initiation (Micro-induction) Suen LW, et al. Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl. JAMA Netw Open. 2025 Jan 2;8(1):e2456253. 60. Lisdexamfetamine for methamphetamine use disorder Ezard N, et al LiMA Investigator Group. Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial. Addiction. 2024 Dec 19. --- This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, visit MI CARES. CME: https://micaresed.org/courses/podcast-addiction-medicine-journal-club/ --- Original theme music: composed and performed by Benjamin Kennedy Audio editing: Michael Bonanno Executive producer: Dr. Patrick Beeman A podcast from Ars Longa Media --- This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice. The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group. --- Email: addictionmedicinejournalclub@gmail.com Facebook: @AddictionMedJC Facebook Group: Addiction Medicine Journal Club Instagram: @AddictionMedJC Threads: @AddictionMedJC YouTube: addictionmedicinejournalclub Twitter/X: @AddictionMedJC --- Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities. Learn more about your ad choices. Visit megaphone.fm/adchoices

Even though GLP-1 drugs have helped nearly 20 million people shed weight across the world since 2021, Indians had to wait until 2025 to get in on the action legally.To be fair, the country wasn't entirely in the dark. Semaglutide—the molecule behind pharma giant Novo Nordisk's blockbuster drugs Ozempic and Wegovy—was already available for diabetes treatment. But this March, Eli Lilly's Mounjaro (which uses a different molecule, tirzepatide) entered the market. In July, Wegovy arrived. And suddenly, India went from “we know GLP-1” to “we want the skinny shot”.Since then, the GLP-1 market in India—across diabetes and weight loss—has grown from Rs 531 crore to Rs 628 crore. And now, depending on the vantage point, things are about to get much bigger. And much cheaper.And naturally, pretty much every major Pharma major wants in on the action. Tune in. Do you work in IT? Take our surveyWant to join The Ken's team? Fill this form. 

TakeawaysThe podcast features Dr. Grant Tinsley, a body composition expert.The discussion revolves around a case series on body composition effects.GLP-1 receptor agonists are a focus of the research.The importance of resistance training in weight loss is emphasized.Patient case studies provide insights into individual experiences.The first patient lost a significant amount of fat mass while preserving lean mass.The second patient achieved remarkable body composition changes in a short time.The third patient showed positive changes over a longer duration.The need for more randomized trials is highlighted.The conversation underscores the role of exercise and nutrition in weight management.Tap or Click here to see more from Dr. GrantTap here for scientific references in this episode.

Send us a textWelcome back Rounds Table Listeners! We are back today with a Classic Rapid Fire episode. This week, Drs. Mike and John Fralick discuss two recent papers: the effects of infrequent zoledronate administration on vertebral fracture prevention in early postmenopausal women, and the efficacy and safety of semaglutide in adults with type 1 diabetes and obesity. Two papers, here we go!Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age (0:00 – 10:24)Semaglutide in Adults with Type 1 Diabetes and Obesity (10:25 – 17:48)And for the Good Stuff (17:49 – 19:46):Canadian tennis player Victoria Mboko wins the Canadian Open!The I'm Pharmacy podcast— coming soon to www.medicinepods.com.Thank you to our sponsor, FIGS scrubs. Rounds Table listeners can save 20% on their next purchase with code FIGSCA at https://www.wearfigs.com/.Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In this episode, we look at the new "wonder drugs" that are wreaking havoc on people's lives.Show NotesAlcor Life Extension Foundation: https://en.wikipedia.org/wiki/Alcor_Life_Extension_FoundationFred and Linda Chamberlain https://en.wikipedia.org/wiki/Fred_and_Linda_Chamberlain Mike Darwin https://en.wikipedia.org/wiki/Mike_DarwinThe Great Ozempic Scam https://www.theburningplatform.com/2024/09/12/the-great-ozempic-scam Semaglutide https://en.wikipedia.org/wiki/Semaglutide Drug trial snapshot:  https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-ozempic Can Ozempic Kill You? https://www.motleyrice.com/diabetes-lawsuits/ozempic/safe-for-weight-loss/deathsTirzepatide, or Mounjaro https://en.wikipedia.org/wiki/Tirzepatide Tirzepatide is a peptide The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist https://pubmed.ncbi.nlm.nih.gov/37800107/ This Is What Happens When You Inject Yourself With Reptile Venom Peptides Marketed as FDA-Approved Weight Loss Drugs https://discernreport.com/this-is-what-happens-when-you-inject-yourself-with-reptile-venom-peptides-marketed-as-fda-approved-weight-loss-drugs/

Dr. Centor discusses outcomes in patients with type 2 diabetes when treated with semaglutide or dulaglutide versus empagliflozin with Drs. Kevin Kip and Anum Saeed.

The most uncensored guest I've ever had. He always has knowledge to share that has me realize there's something new for me I haven't been looking into.The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00:00 – Intro00:03:19 – Caffeine Kickstart00:06:19 – Metabolism & Side Effects Breakdown00:10:55 – Stack Design & Mixing Compounds00:14:48 – Injection Methods & GH Dosing00:20:15 – Practicality in HRT & Nuanced Advice00:25:05 – Injection Scar Tissue & Absorption00:26:56 – Prep Strategy & Mini Cuts00:32:17 – Coaching Approaches & Hormone Levels00:35:14 – Estrogen, Gyno & Anabolics00:41:45 – Healthcare System Critique00:45:40 – Medical Ethics & Corruption00:50:56 – Progress Algorithms & Training Style00:55:45 – Aging, Growth & Rep Ranges01:00:42 – EQ vs Primo & Kidney Concerns01:03:27 – Anecdotal Evidence01:18:43 - Methylene Blue Cancer Risk01:21:11 – Retatrutide & Prep Secrets01:27:08 – Masteron vs Primo & Cycle Choices01:31:54 – Back Growth & Training Pitfalls01:35:35 – Genetic Risks & Bodybuilding Myths01:38:38 – High-Frequency Gains01:40:27 – Final Message & Wrap-Up

In this episode, Mike discusses the latest GLP-1 craze, which has to do with healthy weight individuals using these medications. ------------------------------------------------Click here to apply for coaching!For some amazing resources and to be a part of a badass community, join our FB group HEREThe personality assessment is now available online! Click here to take the assessment and find out what your personality tells us about the way you should be training and eating.Take the assessment here!To learn more about Neurotyping, visit www.neurotypetraining.comFollow Mike on IG at @coach_mike_millner

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.com0:00 – Intro1:55- Prep vs Off-Season Diet4:56 – Stretching before the show6:55 - Dubai Pro Success9:40 – Switching to Machines12:07 – Dealing with Personal Issues15:45 – Coaching Myself17:52 – Stomach Issues & Solutions23:52 – Cutting Compounds Early27:25 – Working with Patrick29:38 – Trusting My Instincts34:00 – Improving Lats41:02 – Leg Training Insights44:39 – Reverse Grip for Lats45:35 – Using Drop Sets & Intensifiers53:34 – GLP-1 & Digestion Concerns1:08:30 – Secrets to Insane Conditioning1:13:20 – Making Weight for Shows1:21:00 – Moderate Peak Week Philosophy1:23:30 – Gradual Carb Increase Strategy1:38:43 – Michaels's Favourite Off-Season1:40:35 – High Doses, No Gains1:49:30 - Compounds that didn't work for Michael1:54:50 – Financing Bodybuilding as a Pro1:59:38 - Mindset is everything2:04:50  - Most important supplements2:07:00 – Final Message to the World

In response to the article I wrote in The Times about whether I was daft for not using skinny jabs to lose weight, I thought revisiting my conversation with Johann Hari about his book Magic Pill, which extensively researched the benefits, limitations and risks of GLP-1 Agonist drugs such as Ozempic, Semaglutide, Wegovy and Mounjaro.Johann is thorough and meticulous in his research and this interview, originally broadcast in 2024, was before weight loss drugs became as mainstream and as widely prescribed as they are today.One of the experts Johann interviewed during his years of research, stated that the cultural impact of GLP-1s was as significant as the smart phone. At the time, it seemed like a very bold statement, but in the year since we spoke, I think it's hard to argue that they haven't completely changed the way we talk about weight, weight loss, diets, food and more...I'd love to hear your thoughts on this episode. Email me at office@emmaguns.com or Subscribe to my Substack and join the chat there. Hosted on Acast. See acast.com/privacy for more information.